➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Colorcon
AstraZeneca
Baxter
McKinsey

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Litigation Details for In Re: Nebivolol ('040) Patent Litigation (N.D. Ill. 2012)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in In Re: Nebivolol ('040) Patent Litigation
The small molecule drug covered by the patent cited in this case is   Start Trial .

Details for In Re: Nebivolol ('040) Patent Litigation (N.D. Ill. 2012)

Date Filed Document No. Description Snippet Link To Document
2012-06-12 1 allegations with respect to U.S. Patent No. 6,545,040 (‘040 patent), which covers the Bystolic drug.…generic versions of the patented Forest drug Bystolic3 before the drug’s patent expires. Bystolic reportedly…complex pharmaceutical patents and the entry of generic versions of the patent holder’s drugs are particularly…ingredients in the patent. Moreover, the issue of the obviousness of the ‘040 patent based on a specific…Brimonidine Patent Litig., 507 F. Supp. 2d 1381 (J.P.M.L. 2007) (same); In re Metoprolol Succinate Patent Litig External link to document
2013-01-25 120 certain claims of United States Patent No. 6,545,040 ("the '040 Patent") in connection with …:7115 the '040 Patent was a technical act of infringement of that patent under 35 U.S.C. § 271(…#39;040 Patent and/or whether the product described by ANDA No. 203821 infringes that patent. …DISTRICT OF ILLINOIS In re Nebivolol ('040) Patent Litigation C.A. No. 12-5026 (EEB) (JC) …Court has subject matter jurisdiction over this patent infringement action (the "Action") and External link to document
2013-01-25 121 infringement of United States Patent No. 6,545,040 ("the '040 Patent") in connection with Torrent…expiration of the '040 Patent was a technical act of infringement of that patent under 35 U.S.C. § 271(…in the '040 Patent within the United States before the expiration of that patent. …DISTRICT OF ILLINOIS In re Nebivolol ('040) Patent Litigation C.A. No. 12-5026 (EEB) (JC) …Court has subject matter jurisdiction over this patent infringement action (the "Action") and External link to document
2013-07-16 143 The disputed claim terms in U.S. Patent No. 6,545,040, along with the parties’ proposed constructions… EASTERN DIVISION In re NEBIVOLOL (’040) PATENT Civil Action No. 1:12-cv…CLAIM CONSTRUCTION CHART Pursuant to Local Patent Rule 4.2(f), Plaintiffs Forest Laboratories, Inc…disease In Re: Nebivolol ('040) Patent Litigation 12 June 2012 16 December External link to document
2013-11-07 160 infringement of United States Patent No. 6,545,040 ("the '040 Patent") in connection with Actavis…expiration of the '040 Patent was a technical act of infringement of that patent under 35 U.S.C. § 271(…#39;040 Patent and/or whether the product described by ANDA No. 203683 infringes that patent. … EASTERN DIVISION In re NEBIVOLOL ('040) PATENT Civil Action No. 1:12-cv-… EASTERN DIVISION In re Nebivolol ('040) Patent Litigation C.A. No. 12-5026 (EEB) (JC) External link to document
2013-12-16 165 infringement of United States Patent No. 6,545,040 ("the '040 Patent") in connection with Actavis…expiration of the '040 Patent was a technical act of infringement of that patent under 35 U.S.C. § 271(…#39;040 Patent and/or whether the product described by ANDA No. 203683 infringes that patent. …EASTERN DIVISION In re Nebivolol ('040) Patent Litigation C.A. No. 12-5026 (EEB) (JC) …Court has subject matter jurisdiction over this patent infringement action (the "Action") and External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Boehringer Ingelheim
AstraZeneca
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.